Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network

PURPOSE: To quantify the hepatic safety of pazopanib and comparator anti-vascular endothelial growth factor (VEGF) therapies in clinical practice among renal cell carcinoma (RCC) patients. METHODS: A population-based cohort study of new anti-VEGF users was conducted in two US healthcare databases, D...

Descripción completa

Detalles Bibliográficos
Autores principales: Shantakumar, Sumitra, Nordstrom, Beth L., Djousse, Luc, Hall, Susan A., Gagnon, David R., Fraeman, Kathy H., van Herk-Sukel, Myrthe, Chagin, Karen, Nelson, Jeanenne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010603/
https://www.ncbi.nlm.nih.gov/pubmed/27438066
http://dx.doi.org/10.1007/s00280-016-3112-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010603/
https://www.ncbi.nlm.nih.gov/pubmed/27438066
http://dx.doi.org/10.1007/s00280-016-3112-9

Ejemplares similares